All In Biotech

Drug Trial Radar · NCT02724163

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Apr 2016

Primary completion

Dec 2031

Study completion Dec 2032

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Assistance Publique - Hôpitaux de Paris; Cancer Research UK; National Cancer Institute, France; Pfizer
First posted
Mar 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is : 1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or liposomal daunorubicin in induction 2. To compare mitoxantrone (anthracenedione) \& cytarabine with liposomal daunorubicin (anthracycline) \& cytarabine as induction therapy. (Randomisation 1 (R1) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.) 3. To compare a single dose of gemtuzumab ozogamicin with the optimum tolerated number of doses of gemtuzumab ozogamicin (identified by the dose-finding study) when combined with induction chemotherapy. 4. To compare two consolidation regimens: high dose cytarabine (HD Ara-C) and fludarabine \& cytarabine (FLA) in standard risk patients. 5. To compare the toxicity and effectiveness of two haemopoietic stem cell transplant (HSCT) conditioning regimens of different intensity: conventional myeloablative conditioning (MAC) with busulfan/cyclophosphamide and reduced intensity conditioning (RIC) with fludarabine/busulfan.

Conditions

  • Acute Myeloid Leukaemia

Interventions

  • Gemtuzumab ozogamicinDrug

    Antibody-conjugated chemotherapy agent.

  • Liposomal daunorubicinDrug

    Anthracycline (Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.

  • MitoxantroneDrug

    DNA-reactive agent

  • FludarabineDrug

    A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.

  • CytarabineDrug

    Pyrimidine nucleoside analogue, an antineoplastic agent.

  • BusulfanDrug

    Alkylsulfonate

  • CyclophosphamideDrug

    A nitrogen mustard alkylating agent from the oxazaphosphorine group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs).Time frame: Incidence of DLTs will be evaluated up to day 45 post course 1 and course 2 of induction chemotherapy.
  2. Event Free Survival (EFS).Time frame: Event free survival (EFS) will be evaluated as the time from randomisation one to the first event, up to 16 years.
  3. Event Free Survival (EFS).Time frame: Event free survival (EFS) will be evaluated as the time from randomisation two to the first event, up to 16 years..
  4. Relapse free survival (RFS).Time frame: Relapse free survival (RFS) will be evaluated as the time of randomisation three to the first relapse or death from any cause, up to 16 years.
  5. Early treatment related adverse reactions.Time frame: Early treatment related adverse reactions will be evaluated at day 100 post-transplant.
  6. Relapse free survival (RFS).Time frame: Relapse free survival (RFS) will be evaluated as the time of randomisation four to the first relapse or death from any cause, up to 16 years.

Locations

68 sites in 6 countries. Site status is shown where the registry gives one.

  • Women and Children's Hospital Adelaide

    Adelaide, Australia

  • Queensland Children's Hospital

    Brisbane, Australia

  • Monash Children's Hospital

    Melbourne, Australia

  • Royal Childrens Hospital

    Melbourne, Australia

  • John Hunter Children's Hopsital

    New Lambton Heights, Australia

  • Perth Children's Hospital

    Perth, Australia

  • Sydney Children's Hospital

    Sydney, Australia

  • The Childrens Hospital At Westmead

    Westmead, Australia

  • Centre Hospitalier Universitaire Amiens - Picardie

    Amiens, France

  • Centre Hospitalier Universitaire D'angers

    Angers, France

  • Centre Hospitalier Regional Universitaire Besancon - Hopital Jean Minjoz

    Besançon, France

  • Centre Hospitalier Universitaire De Bordeaux - Hopital Pellegrin

    Bordeaux, France

  • Centre Hospitalier Regional Universitaire Brest - Hopital Morvan

    Brest, France

  • Centre Hospitalier Universitaire De Caen

    Caen, France

  • Centre Hospitalier Universitaire De Clermont-ferrand

    Clermont-Ferrand, France

  • Centre Hospitalier Universitaire Dijon Bourgogne - Hopital D'enfants

    Dijon, France

  • Centre Hospitalier Universitaire De Grenoble

    Grenoble, France

  • Hopital Jeanne Dr Flandre

    Lille, France

  • Centre Hospitalier Universitaire De Limoges

    Limoges, France

  • Centre Leon Berard

    Lyon, France

  • Hopital De La Timone

    Marseille, France

  • Centre Hospitalier Regional Universitaire Montpellier - Hopital Arnaud-de-villeneuve

    Montpellier, France

  • Centre Hospitalier Universitaire De Nancy

    Nancy, France

  • Centre Hospitalier Universitaire De Nantes

    Nantes, France

  • Centre Hospitalier Universitaire De NICE

    Nice, France

  • Hopital Armand Trousseau

    Paris, France

  • Hopital Robert Debre

    Paris, France

  • Hopital Saint Louis

    Paris, France

  • Centre Hospitalier Universitaire De Poitiers

    Poitiers, France

  • Chu De Reims

    Reims, France

  • Centre Hospitalier Universitaire De Rennes - Hopital Sud

    Rennes, France

  • Centre Hospitalier Universitaire De Rouen

    Rouen, France

  • Centre Hospitalier Universitaire Saint-etienne

    Saint-Etienne, France

  • Strasbourg Hautepierre

    Strasbourg, France

  • Centre Hospitalier Universitaire De Toulouse - Hopital Des Enfants

    Toulouse, France

  • Centre Hospitalier Regional Universitaire De Tours - Hopital Clocheville

    Tours, France

  • Our Lady's Hospital for Sick Children

    Dublin, Ireland

  • Starship Childrens Hospital

    Auckland, New Zealand

  • Christchurch Hospital

    Christchurch, New Zealand

  • Kantonsspital Aarau

    Aarau, Switzerland

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.